Analysis of the Short-Term Curative Effect of Roxadustat in Treating Renal Anemia in Patients with Peritoneal Dialysis

Abstract

Objective: To analyze the short-term curative effect of roxadustat in the treatment of renal anemia in patients with peritoneal dialysis. Methods: 70 patients with peritoneal dialysis renal anemia admitted to the dialysis department of our hospital from March 2021–March 2023 were selected as research objects, divided into a research group and a reference group according to random number drawing method, with each group consisting of 35 cases. The patients in the research group were treated with roxadustat, and those in the reference group were treated with recombinant human erythropoietin. The total efficacy, anemia index, iron metabolism index, and occurrence of adverse reactions were compared between the two groups. Results: The total efficacy of the treatment received in the research group was significantly higher than that in the reference group (P < 0.05). In terms of anemia indicators, there was no statistically significant difference between the hemoglobin (Hb), the red blood cell (RBC), and the hematocrit (HCT) of both groups (P > 0.05) before treatment. After treatment, the anemia indicators of the patients in the research group were significantly better than those in the reference group, (P < 0.05). In terms of iron metabolism, before treatment, there was no significant difference between the total iron-binding capacity (TIBC), the transferrin (TRF), the ferritin (FER), and iron (Fe) of both groups (P > 0.05). After treatment, the research group’s iron metabolism indicators were significantly better than those of the reference group (P < 0.05). The incidence of adverse reactions in the research group was significantly lower than that in the reference group (P < 0.05). Conclusion: The short-term curative effect of roxadustat in the treatment of peritoneal dialysis patients was demonstrated through this study, making it a viable treatment option.